An observational study in Ophthalmia Neonatorum, sponsored by Centre Hospitalier Universitaire, Amiens. Completed at 1 site in France. Open to participants aged 36 Weeks to 36 Weeks. Per ClinicalTrials.gov, last updated 2019-01-23.
Sponsored by Centre Hospitalier Universitaire, Amiens · Observational
The French guidelines for the use of Rifamycine eye drops in delivery room to prevent neonatal conjunctivitis have been actualized. Only newborns exposed to risk factors of conjunctivitis should be treated, compared to previous guidelines, treating all newborns. currently, there are no data describing risk factors for neonatal conjunctivitis. This study evaluated the incidence of conjunctivitis with or without Rifamycine eye drops treatment in the delivery room. Then risk factors for neonatal conjunctivitis where analyzed.
361 studies on the registry are indexed under Conjunctivitis; 17 are open to participants now.
This study's enrollment of 881 is above the median of 152 across 47 observational studies indexed under Conjunctivitis.
Browse Conjunctivitis studies →Centre Hospitalier Universitaire, Amiens is the lead sponsor of 576 studies on the registry; 178 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Newborns
Exclusion Criteria:
Newborns treated with rifamycin eye drops systemically two months before change of practices in delivery room.
Other: Rifamycine treatment
Newborns not treated with antibiotic prophylaxis in a systemic way, according to the new french guidelines of January 1st, 2015.
Other: whithout Rifamycine treatment
Phone prospecting: occurrence of conjunctivitis in newborns treated with rifamycine treatment in delivery room.
Phone prospecting: occurrence of conjunctivitis in newborns did not receive eye drop treatment in delivery room according to new guidelines.
Occurrence of conjunctivitis during the first 8 days of life in newborns
Time frame: 8 days
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ophthalmia Neonatorum
Centre Hospitalier Universitaire, Amiens